Holen Sie sich die Stockscreener-App
0.6393
1.19%
-0.0077
Vorhandelsmarkt:
.62
-0.0193
-3.02%
Schlusskurs vom Vortag:
$0.647
Offen:
$0.659
24-Stunden-Volumen:
95,953
Relative Volume:
0.82
Marktkapitalisierung:
$28.70M
Einnahmen:
$80.28M
Nettoeinkommen (Verlust:
$-38.83M
KGV:
-0.7686
EPS:
-0.8318
Netto-Cashflow:
$-28.67M
1W Leistung:
-5.71%
1M Leistung:
-11.22%
6M Leistung:
-10.89%
1J Leistung:
-62.17%
1-Tages-Spanne:
$0.6303
$0.6799
1-Wochen-Bereich:
$0.6035
$0.70
52-Wochen-Spanne:
$0.5011
$2.00
Tela Bio Inc Stock (TELA) Company Profile
Firmenname
Tela Bio Inc
Sektor
Branche
Telefon
484-320-2930
Adresse
1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA
Compare TELA vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TELA
Tela Bio Inc
|
0.6393 | 29.05M | 80.28M | -38.83M | -28.67M | -0.8318 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tela Bio Inc Stock (TELA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-05-31 | Eingeleitet | Lake Street | Buy |
| 2019-12-03 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-12-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-12-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Tela Bio Inc Aktie (TELA) Neueste Nachrichten
TELA Bio (TELA) CEO adds 12,500 shares in August buy - Stock Titan
TELA Bio (TELA) Q2 2026 Earnings Call Transcript - AOL.com
TELA (TELA) Quarter in Focus: The EPS Result Is Below Expectation under the Current Snapshot; Market Response: The Share Price Sheds 1.08% in the Available RecordProduct Revenue Analysis - Vinanet
TELA (TELA) Close and Levels: Ends Lower by 1.54% at $0.64 in the Latest Session; Chart Reference: the $0.61 to $0.67 Range Remains in Focus on the DayKAMA Signal - Vinanet
SILVERARC CAPITAL MANAGEMENT, LLC Trims TELA Bio Inc (TELA) Stak - GuruFocus
TELA Bio Pulls 2026 Outlook as Sales Fall, Loss Widens - MyChesCo
TELA Bio (TELA) CEO buys 15,000 shares at $0.6978 - Stock Titan
TELA Bio CEO Heather C. Getz acquires common shares worth $10,467 - Bitget
Tela Bio Earnings Call: Growth Meets Execution Risks - TipRanks
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
TELA BIO (TELA): SilverArc Capital and Devesh Gandhi disclose 2.14M-share 4.8% stake - Stock Titan
TELA Bio, Inc. (NASDAQ:TELA) Just Reported And Analysts Have Been Cutting Their Estimates - Moomoo
TELA Stock Price, Quote & Chart - ChartMill
TELA Bio (TELA) Drops 5.86% to $0.68 as Micro-Cap Med-Tech Stock Approaches Critical SupportOvernight Profile - Vinanet
Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report - simplywall.st
TELA Bio, Inc. Revenue Breakdown – BOATS:TELA - TradingView
TELA Bio, Inc. 2026: Revenue $19.29M, EPS ($0.2) — 10-Q Summary - TradingView
TELA Bio (NASDAQ: TELA) faces going concern doubt amid debt covenants and cash burn - Stock Titan
TELA Bio loss hits USD 9.3M in Q2 2026 - Medical Buyer
TELA BIO (TELA): SilverArc and Devesh Gandhi report 4.8% ownership stake - Stock Titan
TELA Bio, Inc. Stock 12‑Month Price Target Cut to $2.1, Implies 126% Upside - TradingView
TELA Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 12.4%One-Time Loss Impact - Vinanet
Tela Bio earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigati - GuruFocus
TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ... - Yahoo Finance
TELA Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
TELA Looks 43.6% Undervalued on GF Value™ Despite Operational Un - GuruFocus
Transcript : TELA Bio, Inc., Q2 2026 Earnings Call, Aug 10, 2026 - marketscreener.com
TELA Bio misses Q2 revenue, withdraws full-year guidance - scanx.trade
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
TELA Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: TELA Bio misses Q2 2026 estimates, withdraws guidance - Investing.com
Is TELA Bio Inc (TELA) Positioned for Recovery After Q2 Earnings Miss? GF Score: 57/100 - GuruFocus
Q2 2026 TELA Bio Inc Earnings Call Transcript - GuruFocus
TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook - TradingView
TELA Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TELA Bio Reports Second Quarter 2026 Financial Results - The Manila Times
BRIEF-TELA Bio Q2 Revenue USD 19.291 Million Vs. IBES Estimate USD 20 Million - TradingView
TELA Bio Withdraws 2026 Revenue Guidance as Sales Fall 4% - Stock Titan
TELA Bio Q2 revenue falls 4% to $19.3 million - Quiver Quantitative
TELA Bio Names Getz CEO as Founder Koblish Steps Aside - MyChesCo
TELA Bio Inc (TELA) Stock Analysis & Forecast - TradingKey
TELA Bio Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
TELA Bio Inc (TELA) Stock News Today - TradingKey
TELA Bio Inc (TELA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
People on the Move: Heather Getz Joins TELA Bio as Chief Executive Officer - BioBuzz
Earnings To Watch: TELA Bio Inc (TELA) Q2 2026 -- GF Value Sees 97% Upside - Yahoo Finance
TELA Q2'26 Earnings: EPS estimate is (0.17) USD - TradingView
TELA Bio (TELA) Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Commercialization CostsEBITDA Analysis - Vinanet
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Large equity grants for TELA Bio, Inc. (TELA) CEO Heather Getz - Stock Titan
Finanzdaten der Tela Bio Inc-Aktie (TELA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):